A medication used for heart conditions improves the efficacy of current treatments for melanoma in mouse models

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, ​​Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d'Alacant, Valencian Community) and IRB Barcelona (Barcelona, ​​Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news